Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04940936
Other study ID # SDM Lung SBRT
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 12, 2021
Est. completion date August 31, 2030

Study information

Verified date October 2023
Source Vejle Hospital
Contact Thomas L Fink, MD
Phone +4579405446
Email thomas.leth.fink@rsyd.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Patient Decision Aid (PtDA) is developed during a workshop in close collaboration with selected patients. The PtDA is subsequently used in the consultation between patient and physician to facilitate their shared decision on the dose of stereotactic body radiation therapy (SBRT) for lung tumors located less than 1 cm from the thoracic wall. Hypothesis: The use of a PtDA will increase the extent of Shared Decision Making (SDM) during the consultation and result in patients being more directly involved in the planning of their treatment.


Description:

When a lung tumor is located close to the thoracic wall, there is an increased risk of developing chest wall pain or rib fracture following SBRT of the tumor. A meta-analysis has shown the pooled risk of chest wall pain to be 11% and that of rib fracture to be 6.3% with significant differences between individual studies. These side effects may occur several years after the treatment. SDM is a collaborative process allowing patients and healthcare professionals to make decisions together taking into account the best scientific evidence as well as patients' values, preferences, life situation, and knowledge about disease process and prognosis. PtDAs are tools designed to assist caregivers in the process of informing patients about relevant treatment options. PtDAs contain factual and balanced information about the options and the pertaining pros, cons, and probabilities. The tools are relevant when the decision is preference-sensitive, that is, the right treatment cannot be decided based on professional knowledge alone. The use of PtDAs has shown to provide a number of positive effects on the patients, including increased knowledge of options, better understanding of risks, and clarity as to what matters most in their life situation. Other effects are decreased decisional conflict and a higher degree of involvement in decision making. This is a randomized trial enrolling eligible patients during a period of 16 months. SDM will be used in the planning of SBRT to patients with peripheral non-small cell lung tumors or lung metastases and offer them the choice between high (66 Gy in 3 fractions) and low (45 Gy in 3 fractions) radiation dose. A total of 40 patients will be included in the study, i.e. 20 patients in each arm.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date August 31, 2030
Est. primary completion date August 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Histologically confirmed or high probability of non-small cell lung cancer, or metastasis from other cancer, located = 1 cm from the thoracic wall. High probability refers to consensus on the diagnosis at the local multi-disciplinary lung tumor conference. - Eligible for stereotactic body radiation therapy in ablative doses (i.e. 66/45 Gy in 3 fractions) following national guidelines (2). - Can read and understand Danish. - Written and orally informed consent. - Performance status 0-2 - Life expectancy > 6 months assessed by the physician during the consultation. Exclusion Criteria: - Previous radiation therapy in the thoracic region (lung, breast or mediastinum), if it is not possible to produce a new radiation plan of 66 or 45 Gy in 3 fractions that considers previous radiation therapy and still complies with all constraints, including dose to the thoracic wall. Previous surgery in the thorax is allowed. - Mental or social conditions preventing full understanding of the information or the planned treatment and follow-up.

Study Design


Intervention

Behavioral:
A Patient Decision Aid
The Patient Decision Aid informs about the pros and cons of each option

Locations

Country Name City State
Denmark Vejle Hospital, Department of Oncology Vejle Region Of Southern Denmark

Sponsors (1)

Lead Sponsor Collaborator
Vejle Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary The extent of shared decision making in the consultation between patient and oncologist as measured by the OPTION tool Minimum value: 0. Maximum value: 48. The higher the value, the higher the extent of SDM during the consultation During the one hour primary consultation.
Secondary Difference in patient perceived level of shared decision making between arm A and B as measured by the tool SDM-Q9. Minimum value 0. Maximum value 45. The higher the value, the higher the patient experienced extent of SDM during the consultation Immediately after the primary consultation
Secondary Difference in patient perceived level of shared decision making between arm A and B as measured by the tool SDM_P4 Minimum value 0. Maximum value 4. The higher the value, the higher the patient experienced extent of SDM during the consultation Immediately after the primary consultation
Secondary Difference in patient perceived level of shared decision making between arm A and B as measured by the tool CollaboRATE Minimum value 0. Maximum value 27. The higher the value, the higher the patient experienced extent of SDM during the consultation Immediately after the primary consultation
Secondary Difference in decisional conflict between patients in arm A and B as measured by the Decision Conflict Scale Minimum value: 0. Maximum value: 64. The higher the value, the more decisional conflict. Immediately after the primary consultation
Secondary Difference in decisional regret between patients in arm A and B as measured by the Decision Regret Scale Minimum value: 5. Maximum value: 25. The higher the value, the more decisional regret. Reported by the patients six months and 3 years after the primary consultation
Secondary Difference in fear of cancer recurrence between patients in arm A and B as measured by the Fear of Cancer Recurrence - Short Form questionnaire Minimum value: 0. Maximum value: 36. The higher the value, the more fear of recurrence. Reported by the patients six months and 3 years after the primary consultation
Secondary Number of patients developing chest wall pain and/or rib fracture during the 5-year follow-up program Evaluated by the physician every three months the first two years and then every six months the following three years. Up to 5 years
Secondary Quality of Life as measured by the questionnaire EORTC QLQ-C30. Thirty questions with two different scales (1-4 and 1-7). The higher the value, the more symptoms/problems.
Completed by the patients every three months the first two years and then every six months the following three years.
Up to 5 years
Secondary Quality of Life as measured by the questionnaire EORTC QLQ-LC29 Twenty-nine questions on a scale from 1 to 4. The higher the value, the more symptoms/problems.
Completed by the patients every three months the first two years and then every six months the following three years.
Up to 5 years
See also
  Status Clinical Trial Phase
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT02058550 - Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy Phase 1
Completed NCT01434290 - Radiation Therapy in Treating Patients With Prostate Cancer Phase 2
Completed NCT01399372 - Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Phase 2
Active, not recruiting NCT00087815 - Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain N/A
Completed NCT01407770 - Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer
Completed NCT00003313 - Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer Phase 3
Completed NCT03783364 - Pre- or Postoperative Accelerated Radiotherapy N/A
Enrolling by invitation NCT04305613 - Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Recruiting NCT06036706 - Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma: N/A
Withdrawn NCT04593914 - A Novel Skin Barrier Protectant for Acute Radiodermatitis N/A
Recruiting NCT04110223 - Validation Studies of Biomarkers for Precision Radiation Oncology in Locally Advanced Solid Tumors
Active, not recruiting NCT02259218 - Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy
Recruiting NCT06073509 - Atrial Fibrillation and Other Cardiac Arrhythmias and Diseases After Radiotherapy for Breast Cancer : Watch Your HeaRT
Withdrawn NCT02017925 - Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation N/A
Completed NCT01170299 - Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer N/A
Completed NCT00974168 - Spinal Cord Compression Re-Treat Study Phase 2
Completed NCT00008398 - Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Phase 3
Enrolling by invitation NCT04047823 - Temperature and Injury in Radiotherapy Radiation Skin Injury